Eisai Clinical Trials

A Phase 2 Study of E7080 in Subjects With Advanced Thyroid Cancer

E7080-J081-208

Study Overview

E7080
lenvatinib
NCT01728623, JapicCTI-122009, jRCT2080221963
Sep 2012 - Oct 2015
Thyroid Cancer
1. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) [Time Frame: Screening visit to 30 days after the last dose of study drug, or assessed up to 3 years]

  • Males and females 20 Years and older (Adult, Older Adult)

  • Completed

  • Phase 2

  • Japan

Results

CSR Synopsis

Download PDF

Lay Summary

Download PDF
Publication reference citation

Takahashi S, Kiyota N, Yamazaki T, Chayahara N, Nakano K, Inagaki L, Toda K, Enokida T, Minami H, Imamura Y, Fukuda N, Sasaki T, Suzuki T, Ikezawa H, Dutcus CE, Tahara M. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer. Future Oncol. 2019 Mar;15(7):717-726. doi: 10.2217/fon-2018-0557. Epub 2019 Jan 14.

Tahara M, Kiyota N, Yamazaki T, Chayahara N, Nakano K, Inagaki L, Toda K, Enokida T, Minami H, Imamura Y, Sasaki T, Suzuki T, Fujino K, Dutcus CE, Takahashi S. Lenvatinib for Anaplastic Thyroid Cancer. Front Oncol. 2017 Mar 1;7:25. doi: 10.3389/fonc.2017.00025. eCollection 2017.

Data Sharing

ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.

CSDR Sharing is available for this study.

CSDR Availability
Clinical Trial Data

Redacted documents may be available upon request for this study.

Document type Availability
Protocol
SAP
Sample CRF
Full CSR